Key Takeaways on KRAS G12C Management

Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, share their key takeaways on managing KRAS G12C-mutated non-small cell lung cancer. Dr. Veluswamy offers three: test every patient for KRAS and its co-occurring mutations, with particular attention to TP53 and STK11, since they alter treatment approach; immunotherapy is effective in KRAS G12C-mutated disease and can offer durable, long-term benefit; and the field is now exploring multiple combination strategies that continue to improve outcomes. Dr. Jani adds that the EMPOWER-Lung 1 findings were especially encouraging, since immunotherapy benefited this population even though the trial's control arm received chemotherapy alone, with crossover permitted only after progression, and he calls for prospective studies to confirm the signal. He also states that he is watching pan-RAS inhibitors closely as they move into clinical trials, expressing optimism about their potential role across KRAS-mutated non-small cell lung cancer.